Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NT5E | P21589 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.69 |
| ▸ | GLI1 | P08151 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | RORC | P51449 | 1/20 | 0.69 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.69 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 2/20 | 0.66 |
| ▸ | CES1 | P23141 | 2/20 | 0.66 |
| ▸ | F3 | P13726 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betunolic Acid SCHEMBL19147039 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL13098064 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL14436770 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL14111993 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL13573800 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL13908772 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL14397742 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL14447472 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL13814592 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betunolic Acid SCHEMBL8283296 | 1.00 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252155-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT INHIBITING THE GROWTH OF MICRO-ORGANISMS AND FOR MAXIMIZING THE EFFECT | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | disclosed |
| EP-2252154-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | disclosed |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | BIONICHE ANIMAL HEALTH USA, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | BIONICHE ANIMAL HEALTH USA, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2014071506-A1 | COMPOUNDS FOR REDUCING GLUCOCORTICOIDS, AND METHODS OF TREATMENT THEREOF | BIONICHE LIFE SCIENCES INC. (CA) | 2014-05-15 | — | — | WO | disclosed |
| US-8496974-B2 | Method for preparing a composition comprising a compound mixture and a carrier agent | OY GRANULA AB LTD (FI) | 2013-07-30 | — | — | US | disclosed |
| US-8496974-B2 | Method for preparing a composition comprising a compound mixture and a carrier agent | OY GRANULA AB LTD (FI) | 2013-07-30 | — | — | US | disclosed |
| US-8431170-B2 | Antimicrobial composition with low cytotoxicity | OY GRANULA AB LTD. (FI) | 2013-04-30 | — | — | US | disclosed |
| US-8431170-B2 | Antimicrobial composition with low cytotoxicity | OY GRANULA AB LTD. (FI) | 2013-04-30 | — | — | US | disclosed |
| WO-2013038314-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | disclosed |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | INSTITUT NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) | 2010-04-08 | — | — | US | disclosed |
| US-20080293682-A1 | Novel Betulinic Acid Derivatives | DABUR PHARMA LIMITED (IN) | 2008-11-27 | — | — | US | disclosed |
| US-20080293682-A1 | Novel Betulinic Acid Derivatives | DABUR PHARMA LIMITED (IN) | 2008-11-27 | — | — | US | disclosed |
| US-7414042-B2 | Method and composition for selectively inhibiting melanoma | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414042-B2 | Method and composition for selectively inhibiting melanoma | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007141392-A2 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141391-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141389-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141390-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIVIRAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141383-A1 | BETULIN DERIVED COMPOUNDS AS ANTI-FEEDANTS FOR PLANT PESTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293682-A1 | Novel Betulinic Acid Derivatives | BET1, PGGT1B, RABGGTB | GPBAR1 84/4885LMNA 1944/4885NT5E 2619/4885 |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | GART, DNPEP, IL4I1 | GPBAR1 516/4885LMNA 2743/4885NT5E 551/4885 |
| US-20150272922-A1 | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof | NR3C1, NR5A1, NR3C2 | GPBAR1 230/4885LMNA 3994/4885NT5E 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.